ImmunAbs Employee Directory

ImmunAbs has 11-50 employees.

Employees by Department

Departments

Number of employees

Engineering & Technical

4

C-Suite

2

Operations

1

Sales

1

Finance

1

ImmunAbs CEO

DK
Dongjo KimChief Executive Officer
PhonePhoneEmailEmail
See Profile

Key Employees of ImmunAbs

  • KK
    Kisu Kim

    Head of Research & Development

    PhonePhoneEmailEmail
  • PhonePhoneEmailEmail
  • PhonePhoneEmailEmail
  • PhonePhoneEmailEmail
  • PhonePhoneEmailEmail
  • PhonePhoneEmailEmail

ImmunAbs Global Presence

globalPresence illustration
Asia1-10
North America1-10

Index of contact profiles from ImmunAbs

Hundreds of professionals searching for ImmunAbs have connected with key decision-makers. Join them?
Contact Name
Contact Info
Job Title
HQ Location
12

Frequently Asked Questions Regarding ImmunAbs Employees

How many employees does ImmunAbs have?
ImmunAbs has 11-50 employees
Who is the CEO of ImmunAbs?
ImmunAbs’s CEO is Dongjo Kim
Who are ImmunAbs key employees?
Some of ImmunAbs key employees are Kisu Kim
How do I contact ImmunAbs?
ImmunAbs Contact Info: Phone number: +82 269510584 Website: www.immunabs.com
What does ImmunAbs do?

ImmunAbs was established in 2017 by experts of global standard antibody therapeutics development. Our vision is "Hope for Patients, Dreams for Everyone. Currently, we have several antibody therapeutics in global standard development. Antibody is a protein produced by B cell that plays an important role in humoral immunity. Antibodies can specifical... ly bind to various foreign objects and mediate immune responses. Due to the specificity, high affinity, and ability to mediate various efficacy, antibodies have been developed as therapeutics since 1985. So far, more than 90 antibody therapeutics have been licensed for various indications. Of the top 10 world's best-selling drugs in 2019, seven were antibody therapeutics. Antibody therapeutic development requires various know-hows throughout the process, from screening candidates and manufacturing to characterization, BLA approval, and commercialization. ImmunAbs develops antibody therapeutics for orphan diseases, diabetic retinopathy, and diabetes based on its experience in developing antibody therapeutics that have been globally approved for sales in the U.S. and Europe.Read More

Is ImmunAbs a public company?
ImmunAbs is private company therefore does not currently have an official ticker symbol
See more information about ImmunAbs Employees

Get Started with ZoomInfo

Register for free

Sign Up for Free

Get started for free! No credit card needed. Enjoy up to 25 free contacts each month at no cost.
Elevate your prospecting to the next level

Supercharge Your Prospecting

Search ZoomInfo's database of 106M+ companies and 140M+ professionals to find your next lead.
Expand your business

Grow Your Business

Reveal both personal and business contact details, including emails and phone numbers, and close your most valuable buyers.